Effect of Antioxidant Intake on Resistin Levels In Patients With Gum Disease and Diabetes

Effect of Systemic Administration of ALA (Alpha Lipoic Acid) as an Adjunct to Scaling and Rootplaning on Serum Resistin Levels in Patients With Chronic Periodontitis and Type 2 Diabetes Mellitus

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02775266

Acronym

EARGD

Enrollment

Registered

2016-05-17

Start date

2016-02-29

Completion date

2016-10-31

Last updated

2017-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Periodontitis

Brief summary

To evaluate the effectiveness of non surgical periodontal therapy in addition to antioxidant(ALA) on resistin levels in patients with type 2 diabetes and periodontal disease

Detailed description

A total of 40 patients with diabetes and chronic periodontitis attending the department of periodontics will be recruited in the study. 40 subjects will be randomly divided into two groups(control group and test group with 20 subjects in each group). Clinical parameters such as gingival index, periodontal index, random blood sugar levels(RBS) and glycosylated hemoglobin levels (Hb1aC) will be recorded at baseline and after 3 months and 2ml of blood sample will be collected by venepuncture ( baseline and after 3 months) and stored in Ethylenediaminetetraacetic acid containing vials to identify the levels of resistin in the patients by Enzyme linked immunosorbent assay. Group A will receive Alpha lipoic acid at baseline for a period of 3 months. Both the groups will receive scaling and rootplaning at baseline.

Interventions

OTHERAlpha lipoic acid

Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.

PROCEDUREScaling and Root planing

Scaling and root planing will be done at baseline.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

35 Years to 60 Years

Healthy volunteers

Inclusion criteria

Diabetic patients with Chronic periodontitis. \-

Exclusion criteria

Smokers, Pregnant & lactating women, Prior periodontal therapy within 3 months.

Design outcomes

Primary

Measure	Time frame	Description
Serum Resistin Levels and HBAIC Levels	3 months	2ml of blood sample will be collected by venepuncture at baseline and after 3 months and will be assessed by ELISA stored in EDTA containing vials to identify the levels of resistin in the patients by ELISA. Glycosylated hemoglobin levels (Hb1aC) will be recorded at baseline and after 3 months and assessed by Spectrophotometer.

Secondary

Measure	Time frame	Description
Gingival Index	3 months	Gingival index was recorded with william's periodontal probe at baseline and after 3 months
Probing pocket depth	3 months	Were recorded with william's periodontal probe at baseline and after 3 months
Clinical Attachment levels	3 Months	Were recorded with william's periodontal probe at baseline and after 3 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026